Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Hepato-protective Effect of Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

NCT07020377 is registered in ClinicalTrials.gov with Amira Bisher,PhD as lead sponsor.

NCT NCT07020377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07020377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Hepato-protective Effect of Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)
Lead sponsor
Amira Bisher,PhD
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 15, 2024
Completion date
December 30, 2025
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, non alcholic fatty liver disease